Meta AnalysisID 258
地黄治疗乳腺癌患者围绝经期综合征：系统评价与Meta分析
CRD42022384810
Whether could breast cancer patients with perimenopausal syndrome benefit from Chinese herbal medicine with Rehmannia glutinosa as the monarch drug（a drug that plays a major therapeutic role in a prescription）? How do mo
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 258
- Evidence Id
- 8816
- Core Evidence Id
- 8816
- Source Meta Analysis Id
- 241
- Herb2 Meta Analysis Id
- HBMA000241
- Crd Id
- CRD42022384810
- Title
- Rehmannia glutinosa for perimenopausal syndrome in breast cancer patients: a systematic review and meta-analysis
- Review Question
- Whether could breast cancer patients with perimenopausal syndrome benefit from Chinese herbal medicine with Rehmannia glutinosa as the monarch drug（a drug that plays a major therapeutic role in a prescription）? How do modified Kupperman symptoms score change after taking Chinese herbal medicine with Rehmannia glutinosa as the monarch drug comparing with western medicine therapy?
- Study Type Included
- Randomized controlled trials will be included
- Condition Being Studied
- Breast cancer is a common malignant tumor that is more prevalent in women and its incidence has been on the rise in recent years. Chemotherapy and endocrine therapy play an important role in the treatment of breast cancer, but those treatments will lead to perimenopausal syndrome such as hot flushes， sweating, irritability, insomnia, depression, fatigue, and palpitations, which seriously affect patients' quality of life and confidence in treatment. The main treatment for perimenopausal syndrome is hormone replacement therapy, but hormone replacement therapy is not indicated for patients with breast cancer. Oral Chinese medicine is also a treatment for perimenopausal syndrome in breast cancer patients, but there are many different formulas. Chinese herbal medicines with Rehmannia glutinosa as the monarch drug（a drug that plays a major therapeutic role in a prescription） are one of the important types of formulas.
- Participant
- Inclusion criteria： Adults with pathologically diagnosed breast cancer who also have the perimenopausal syndrome(as diagnosed by a clinician, or using any recognized diagnostic criteria). exclusion criteria： 1. Adults with mental illness, severe gynecological disease, and other serious medical conditions 2. Pregnant and lactating women 3. Adults who are participating in other clinical drug trials or using drugs that may affect the results of the clinical observation
- Animal
- Human Disease Modelled
- Intervention
- Chinese herbal medicines with Rehmannia glutinosa as the monarch drug（a drug that plays a major therapeutic role in a prescription） were the main intervention.
- Comparator Control
- Control intervention is western medicine therapy (e.g., tamoxifen, letrozole, oryzanol, Remifemin, Vitamin B1).
- Main Outcome
- Mean change of modified Kupperman symptoms score Measures of effect MD
- Outcome Measure
- Additional Outcome
- Physical status （assessed by Karnofsky Performance score), quality of life（assessed by the Functional Assessment of Cancer Therapy - Breast， FACT-B）, gonadal hormone concentrations（E2, FSH, LH), tumor markers(CEA, CA125, CA153), T cell subset（CD4, CD8, CD4/CD8)
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Breast Neoplasms; Female; Humans; Medicine, Chinese Traditional; Perimenopause; Prescriptions; Rehmannia; Syndrome
- Contact
- Junmiao Xu [email protected]
- Organisational Affiliation
- Hangzhou Women’s Hospital https://www.hzwmhp.com
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-12-18
- Registration Date
- 2022-12-29
- Anticipated Start Date
- 2022-04-15
- Anticipated Completion Date
- 2023-04-15
- Title Cn
- 地黄治疗乳腺癌患者围绝经期综合征：系统评价与Meta分析
- Title En
- Rehmannia glutinosa for perimenopausal syndrome in breast cancer patients: a systematic review and meta-analysis
- Bilingual Status
- complete